Effects of Oral Collagen Drinks on Human Skin

TCI Co., Ltd.105 enrolled

Overview

The objective of this study is to evaluate the effect of oral collagen drink and MAXI collagen drink on human skin condition improvement.

This study is a single-center, double-blinded, parallel human trial designed to evaluate the skin beauty effect of oral collagen drink and MAXI collagen drink. Healthy adult participants aged 18-60 years will be enrolled. Participants will be informed to consume test samples daily for 4 consecutive weeks. Skin measurement and self-assessment questionnaires will be conducted at baseline (before intake), after 1 week, and 4 weeks of consumption.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

105

Conditions

Skin Condition Collagen Synthesis

Interventions

Collagen DrinkDIETARY_SUPPLEMENT

consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 5 g Collagen Powder

MAXI Collagen DrinkDIETARY_SUPPLEMENT

consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 15 mL MAXI Collagen Liquid (equivalent to 5 g of deep hydrolyzed collagen net weight)

MAXI Collagen Drink_High doseDIETARY_SUPPLEMENT

consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 30 mL MAXI Collagen Liquid (equivalent to 10 g of deep hydrolyzed collagen net weight)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy Chinese subjects aged 18 to 60 years, both male and female. * Wrinkle Severity: Crow's feet graded 2-4; under-eye fine lines graded 2-5; nasolabial folds graded 1-3. * Presence of facial skin laxity and sagging. * Ability to undergo skin examinations and pre-treatment in the designated test areas. * Ability to understand the trial process, participate voluntarily, and sign a written Informed Consent Form (ICF). Exclusion Criteria: * Pregnant or lactating women, or those planning to become pregnant in the near future. * Highly sensitive constitution, history of allergic diseases, or history of allergies to cosmetics. * Presence of skin diseases (e.g., psoriasis, eczema, atopic dermatitis, severe acne) or other chronic systemic diseases. * Skin conditions in the test area such as birthmarks, hyperpigmentation, inflammation, scars, nevi (moles), or hypertrichosis (excessive hair). * Use of anti-inflammatory drugs (e.g., oral or topical corticosteroids) within the past month. * Use of cosmetics or other products with similar efficacy within the past 2 weeks. * Participation in other human clinical trials for cosmetics within the past month. * Any other conditions deemed unsuitable for participation based on clinical assessment.

Locations (1)

Beijing Ewish Testing Technology Co.,ltd.

Beijing, China

Outcomes

Primary Outcomes

The change of collagen fiber fluorescence intensity

SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to evaluate the density and quality of dermal collagen fibers.

Time frame: Change from Baseline collagen intensity at 4 weeks

Secondary Outcomes

The change of skin elasticity

Cutometer® MPA580 (CK, Germany) was utilized to measure the gross elasticity of the skin using suction method.

Time frame: Change from Baseline skin elasticity at 4 weeks

The change of skin firmness

Cutometer® MPA580 (CK, Germany) was utilized to measure skin firmness and the area under the suction curve.

Time frame: Change from Baseline skin firmness at 4 weeks

The change of epidermal thickness

SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to measure the depth of the epidermal layer using optical imaging.

Time frame: Change from Baseline epidermal thickness at 4 weeks

The change of cheek skin roughness

AEVA-HE (EOTECH, France) was utilized to measure the arithmetic average roughness (Ra value) of the cheek surface.

Time frame: Change from Baseline skin roughness at 4 weeks

The change of the Dermal-Epidermal Junction (DEJ) structures

SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to assess the structural integrity and epithelial-connective tissue interface (ECTI) of the DEJ.

Time frame: Change from Baseline DEJ status at 4 weeks

The change of nasolabial folds volume

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.